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Ambition  is  a  strong  desire  to  do  or  achieve  something  and
being  ambitious  is  having  or  showing  a  strong  desire  and
determination  to  succeed.  Ambition  is  really  required  to  try
to  summarise  the  new  advances  in  management  of  chronic
obstructive  pulmonary  disease  (COPD)  in  a  series  of  articles,
but  the  Portuguese  Journal  of  Pulmonology  has  demon-
strated  to  be  ambitious  and  is  publishing  four  articles  that
provide  an  overview  of  the  new  concepts  that  are  important
for  the  clinician  that  cares  for  patients  with  this  disease.1--4
The  ﬁrst  topic  is  the  evaluation  of  the  patient  in  order
to  select  the  best  treatment  option.  COPD  is  charac-
terised  by  non-fully  reversible  airﬂow  obstruction.  However,
apart  from  this  common  characteristic,  patients  may
have  absolutely  different  clinical  characteristics  and  symp-
toms.  Moreover,  these  different  clinical  characteristics  may
reﬂect  different  responses  to  the  available  treatments.  The
concept  of  a  clinical  phenotype  of  COPD  was  introduced
to  identify  patients  that  share  clinical  characteristics  and
response  to  therapy.5 But,  which  are  the  relevant  phe-
notypes?  How  many  are  they?  Fragoso  et  al.1 propose  an
answer  to  these  questions.  Basically,  they  propose  the  same
phenotypes  previously  described  in  the  Spanish  Guidelines
for  COPD,6 and  later  adopted  in  other  guidelines  such  as
the  Czech7 and  the  Finnish,8 namely  non-exacerbators,
exacerbators  with  chronic  bronchitis,  exacerbators  with
emphysema  and  asthma-COPD  overlap  syndrome  (ACOS),
with  the  addition  of  the  COPD-bronchiectasis  phenotype.
This  classiﬁcation  makes  a  lot  of  sense  because  it  is
based  on  clinical  grounds  and  is  easy  to  apply  in  general
clinical  practice.  Furthermore,  these  phenotypes  identify
patients  that  require  a  different  therapeutic  approach.9
Non-exacerbators  must  be  treated  only  with  bronchodila-
tors,  ACOS  must  receive  a  combination  of  bronchodilators
and  inhaled  corticosteroids  (ICS),10 patients  with  chronic
bronchitis  may  respond  to  drugs  such  as  roﬂumilast  or  N-
acetylcystein  and  patients  with  bronchiectasis  may  respond
to  long-term  macrolides.6 Obviously  these  phenotypes  are
not  clear-cut,  but  they  are  a  good  guidance  for  the  type  of
treatment  that  must  be  chosen  as  ﬁrst-line.  In  any  case,  we
need  to  remember  that  no  classiﬁcation  will  ever  substitute
the  clinical  judgement  made  by  the  experienced  physician.
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The  second  step  after  initiating  a treatment  is  to  acess
he  response.  It  is  not  clear  how  to  evaluate  the  response  to
herapy  in  COPD;  we  can  evaluate  the  improvement  in  lung
unction,  in  symptoms,  the  absence  of  exacerbations,  the
eduction  in  the  use  of  rescue  medication  and  the  increase
n  the  levels  of  physical  activity,  but  some  of  these  indica-
ors  may  not  change  despite  successful  treatment  and  not
ll  of  them  may  mean  the  same.  This  is  why  there  has  been
 growing  interest  in  the  concept  of  control  of  COPD.  Soler-
atalun˜a  et  al.11 published  a  proposal  for  a  standardisation
f  control  that  is  in  the  process  of  validation.  Guimaraes
t  al.2 present  an  interesting  review  of  the  concept  of  con-
rol  in  COPD  and  indicate  that  unfortunately  there  are  no
vailable  biomarkers  about  the  response  to  treatment  and
o  consensus  exists  about  the  concept  of  control.  However,
t  is  quite  likely  that  we  will  see  some  advances  in  this  area
n  the  future.
But  the  key  question  is  how  can  we  provide  the  best  treat-
ent  for  our  patients  with  COPD?  I  really  do  not  think  that
etters  and  numbers  will  help  us  (A,  B,  C1,  D2,  etc.).12 The
ractice  of  medicine  is  based  on  observation  and  descrip-
ion  and  we  have  to  describe  the  clinical  phenotypes  that
redict  response  to  treatment7 and  don’t  get  lost  in  arti-
cial  classiﬁcations.13 This  is  in  line  of  the  proposal  of  a
atient-oriented  treatment  as  described  by  Ferreira  et  al.3
bviously,  we  do  not  have  all  the  answers,  but  at  least
e  know  the  questions  and  many  groups  are  working  to
etter  identify  responders  to  COPD  treatments.  Ferreira
t  al.3 describe  an  algorithm  for  treatment  of  COPD  based
n  the  existing  evidence.  This  algorithm  recognises  the  cen-
ral  role  of  bronchodilators,  and  in  particular  the  association
ABA/LAMA,  which  is  (or  should  be)  the  basis  of  treat-
ent  of  COPD.6--8 My  only  concern  is  the  inclusion  of  ICS
n  individuals  with  exacerbations.  There  is  no  doubt  that
CS  have  an  effect  on  reduction  of  exacerbations;  but  in  all
atients?  There  is  accumulating  evidence  that  only  patients
ith  a  type  of  inﬂammation  that  is  responsive  to  ICS  (Th2  or
osinophilic  inﬂammation)  will  respond  to  ICS  with  a  reduc-
ion  in  exacerbations,8,14,15 whereas  patients  with  infective
bacterial  and  neutrophilic)  exacerbations  may  be  worse  off
ith  ICS  compared  with  bronchodilators  increasing  the  risk
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f  pneumonia.15,16 Therefore  the  role  of  ICS  in  the  manage-
ent  of  COPD  must  be  revisited.17,18
Finally,  Ferreira  et  al.4 introduce  the  debate  about  a
tepwise  approach  to  therapy  or  ‘‘hit  hard’’,  starting  with  a
ombination  of  drugs  to  obtain  the  maximum  improvement
rom  the  beginning  and  then  reduce  therapy  to  maintain  the
ame  improvement  with  the  minimum  number  of  drugs.  This
s  an  interesting  topic,  and  in  fact,  guidelines  differ  in  their
nterpretation  and  recommendations.19 So  far,  COPD  has
een  considered  a  progressive  disease  and,  as  such,  treat-
ents  have  been  added  during  the  course  of  the  disease.
urprisingly,  even  mild  patients  end  up  with  triple  therapy
LABA/LAMA/ICS)  during  the  course  of  the  disease.20 Clearly,
ot  all  patients  require  triple  therapy  and  in  particular,  not
ll  patients  require  ICS.  Therefore,  step  down  therapy  must
e  possible  and  patients  that  do  not  suffer  from  exacerba-
ions  should  have  their  ICS  treatment  discontinued.17,18
In  summary,  there  are  a  number  of  challenges  in  COPD
anagement,  to  mention  only  a  few:  (1)  reduce  infra-
iagnosis,  (2)  investigate  if  early  therapy  with  maximal
ronchodilatation  (LABA/LAMA)  has  long  term  beneﬁts,
3)  better  characterize  the  patients  that  require  ICS,  (4)
evelop  an  easy  to  use  tool  to  evaluate  control  in  COPD,
5)  deﬁne  the  role  of  second-line  therapies  (ICS,  mucolytics,
acrolides,  phosphodiesterase  4  inhibitors),  and  (6)  develop
n  algorithm  based  on  clinical  phenotypes,  easy  to  use  in
linical  practice.  I  am  sure  that  the  intense  research  in  COPD
ill  give  us  some  answers  in  the  near  future;  in  the  mean-
ime  I  am  sure  that  reading  these  articles  will  provide  some
‘food  for  thought’’  in  this  very  exciting  ﬁeld  of  research.
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